Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco.
Anne F
AF
Luetkemeyer
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts.
Susan L
SL
Rosenkranz
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts.
Darlene
D
Lu
Fundacao Oswaldo Cruz, Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil.
Beatriz
B
Grinsztejn
IMPACTA, Lima, Peru.
Jorge
J
Sanchez
Joint Clinical Research Center, Kampala, Uganda.
Michael
M
Ssemmanda
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.
Ian
I
Sanne
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa.
Helen
H
McIlleron
HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco.
Diane V
DV
Havlir
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
David W
DW
Haas
D000480:Alkynes; D000995:Antitubercular Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D001191:Arylamine N-Acetyltransferase / Q000235:genetics* / Q000378:metabolism; D048588:Benzoxazines / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D003521:Cyclopropanes; D065702:Cytochrome P-450 CYP2B6 / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications; D006801:Humans; D008297:Male; D010568:Peru; D010597:Pharmacogenetics; D012293:Rifampin / Q000627:therapeutic use*; D013019:South Africa; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D014454:Uganda
D000480:Alkynes; D000995:Antitubercular Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D065702:Cytochrome P-450 CYP2B6; D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human; C098320:efavirenz; D012293:Rifampin
HIV/AIDS; efavirenz; pharmacogenetic; rifampin; tuberculosis